Skip to main content

Advertisement

SpringerLink
Log in

Oligodendroglioma

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Before treatment can be initiated, an accurate histopathologic diagnosis must be made. There is still some controversy regarding histologic criteria for the diagnosis of oligodendroglioma and which grading system is best. Molecular diagnosis is becoming an important adjunct to traditional histopathologic diagnosis. For low-grade oligodendrogliomas, maximal surgical resection should be attempted if technically feasible. Radiation therapy or chemotherapy should be deferred unless the patient has significant neurologic symptoms or growth of tumor. Aggressive or anaplastic tumors should also be treated with maximal surgical resection. Increasingly, chemotherapy is replacing radiation therapy as the initial postoperative treatment, with radiation therapy being either delayed until after completion of chemotherapy or, in select patients, deferred until recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coons SW, Johnson PC, Scheithauer BW, et al.: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381–1393.

    Article  PubMed  CAS  Google Scholar 

  2. Daumas-Duport C, Varlet P, Tucker M-L, et al.: Oligodendrogliomas: part 1—patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J. Neurooncol 1997, 34:37–59.

    Article  PubMed  CAS  Google Scholar 

  3. Cairncross JG and Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360–364.

    Article  PubMed  CAS  Google Scholar 

  4. Cairncross JG, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12:2013–2021. This important phase II study established that anaplastic oligodendrogliomas respond to chemotherapy.

    PubMed  CAS  Google Scholar 

  5. Cairncross JG, Ueki K, Zlatesou MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479. A landmark paper showing the link between chemosensitivity and survival and allelic loss of 1p.

    Article  PubMed  CAS  Google Scholar 

  6. Leighton G, Fisher B, Bauman G, et al.: Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol 1997, 15:1294–1301.

    PubMed  CAS  Google Scholar 

  7. Celli P, Nofrone I, Palma L, et al.: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994, 35:1018–1035.

    Article  PubMed  CAS  Google Scholar 

  8. Gannett DE, Wisbeck WM, Silbergeld DL, et al.: The role of postoperative radiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Physics 1994, 30:567–573.

    CAS  Google Scholar 

  9. Shaw EG, Scheithauer BW, O’Fallon JR, et al.: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992, 76:428–434.

    PubMed  CAS  Google Scholar 

  10. Mork SJ, Lindegaard KF, Halvorsen TB, et al.: Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985, 63:881–889.

    PubMed  CAS  Google Scholar 

  11. Paleologos NA, Vick NA, Kachoris JP: Chemotherapy for low-grade oligodendrogliomas? Ann Neurol 1994, 36:294–295.

    Google Scholar 

  12. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203–207.

    PubMed  CAS  Google Scholar 

  13. Paleologos NA, Macdonald DR, Vick NA, et al.: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 1999, 53:1141–1143.

    PubMed  CAS  Google Scholar 

  14. Glass J, Hochberg FH, Gruber ML, et al.: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992, 76:741–745.

    Article  PubMed  CAS  Google Scholar 

  15. Kyritsis AP, Yung WK, Brunner J, et al.: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993, 32:365–371.

    Article  PubMed  CAS  Google Scholar 

  16. Peterson K, Paleologos N, Forsyth P, et al.: Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996, 85:597–601.

    Article  PubMed  CAS  Google Scholar 

  17. Lindegaard K-F, Mork SJ, Eide GE, et al.: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987, 67:224–230.

    PubMed  CAS  Google Scholar 

  18. Cairncross G, Swinnen L, Bayer R, et al.: Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. J Neurooncol 2000, 2:114–119.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Evanston Northwestern Healthcare, 2560 Ridge Avenue, 60201, Evanston, IL, USA

    Nina A. Paleologos MD

Authors
  1. Nina A. Paleologos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paleologos, N.A. Oligodendroglioma. Curr Treat Options Neurol 3, 59–66 (2001). https://doi.org/10.1007/s11940-001-0024-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-001-0024-7

Keywords

Search

Navigation